{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:29:08Z","timestamp":1771572548939,"version":"3.50.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>The alarming rate of drug-resistant tuberculosis (DR-TB) globally is a threat to treatment success among positive tuberculosis (TB) cases. Studies aimed at determining the prevalence, trend of DR-TB and socio-demographic and clinical risk factors contributing to DR-TB in the four regions of Ghana are currently unknown. This study sought to determine the prevalence and trend of DR-TB, identify socio-demographic and clinical risk factors that influence DR-TB, and analyse the relationship between underweight and adverse drug reactions and treatment outcomes among DR-TB patients in four regions of Ghana.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>It was a retrospective review conducted over 5 years, from January 2018 to the end of December 2022. The data were retrieved from the DR-TB registers and folders at the Directly Observed Treatment (DOT) centres in the four regions. Analysis of the data was conducted using STATA version 17.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The prevalence of DR-TB in Ashanti was 10.1%, Eastern 5.3%, 27.8% in Central, and 2.7% in the Upper West region for the year 2022. The overall prevalence rate of DR-TB for the period 2018\u20132022 was 13.8%. The socio-demographic and clinical risk factors that influence DR-TB in the four regions are: age, marital status (aOR 3.58, P-value&lt; 0.00, 95% CI 2.86\u20134.48), Senior High School (SHS) level of education (aOR 2.09, P-value\u2009=\u20090.01, 95% CI 1.21\u20133.63), alcohol intake (aOR 0.49, P-value &lt;0.00, 95% CI 0.38\u20130.63), previously treated (aOR 22.03, P-value&lt;0.00, CI 16.58\u201329.26), major adverse drug reaction (aOR 125.50, P-value&lt;0.00, 95% CI 58.05\u2013271.34), and minor adverse drug reaction (aOR 23.59, P-value&lt;0.00, 95% CI 18.32\u201330.39); treatment outcome, cure (aOR 0.52, P-value&lt;0.00, 95% CI 0.41\u20130.66), completed (aOR 9.67, P-value&lt;0.00, 95% CI 6.56\u201314.28), relapsed (aOR 2.62, P-value\u2009=\u20090.01, 95% CI 1.33\u20135.18), Lost-to-Follow-up (LTFU) (aOR 0.45, P-value&lt;0.00, 95% CI 0.29\u20130.70), and failure (aOR 35.24, P-value&lt;0.00, 95% CI 7.76\u2013159.99). Also, there was an association between underweight and adverse drug reaction (RRR 5.74, P-value&lt;0.00, 95% CI 4.86\u20136.79) and treatment outcome (RRR 0.79, P-value&lt;0.00, 95% CI 0.74\u20130.86).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The study shows that the prevalence of DR-TB in Ghana is low, probably not because the cases have reduced but due to inadequate GeneXpert machines to detect the cases. Age, marital status, education, alcohol intake, previously treated TB cases, adverse drug reactions, underweight, and treatment outcome are factors influencing the development of DR-TB. Therefore, interventions aimed at improving the nutritional status of DR-TB cases and minimising adverse drug reactions will improve treatment outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0331958","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:27:44Z","timestamp":1757438864000},"page":"e0331958","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and factors influencing drug-resistant tuberculosis in four regions of Ghana"],"prefix":"10.1371","volume":"20","author":[{"given":"Esther","family":"Ba-Iredire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-8137","authenticated-orcid":true,"given":"James Atampiiga","family":"Avoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Abanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail Awaitey","family":"Darkie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel Junior","family":"Attombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Agboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"pone.0331958.ref001","volume-title":"Implementing the end TB strategy: the essentials, 2022 update","author":"WHO","year":"2022"},{"key":"pone.0331958.ref002","volume-title":"Consolidated guidance on tuberculosis data generation and use. Module 1. Tuberculosis surveillance","year":"2024"},{"key":"pone.0331958.ref003","first-page":"1","volume-title":"2024 Global tuberculosis report","author":"WHO","year":"2024"},{"key":"pone.0331958.ref004","volume-title":"Global tuberculosis report 2018","author":"WHO","year":"2018"},{"key":"pone.0331958.ref005","volume-title":"Global Tuberculosis report, 2019","author":"WHO"},{"key":"pone.0331958.ref006","doi-asserted-by":"crossref","unstructured":"Bhering P, et al. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de. 2019:1\u201314.","DOI":"10.1101\/656884"},{"issue":"1","key":"pone.0331958.ref007","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1186\/s12889-019-7838-2","article-title":"Time to poor treatment outcome and its predictors among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara region, Ethiopia: retrospective cohort study","volume":"19","author":"DB Ketema","year":"2019","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0331958.ref008","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1186\/s12879-019-4411-7","article-title":"Intensive phase treatment outcome and associated factors among patients treated for multi drug resistant tuberculosis in Ethiopia: a retrospective cohort study","volume":"19","author":"T Molie","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0331958.ref009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5588\/pha.16.0055","article-title":"Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India","volume":"7","author":"D Nair","year":"2017","journal-title":"Public Health Action"},{"issue":"3","key":"pone.0331958.ref010","article-title":"Xpert MTB\/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum","volume":"59","author":"Y Cao","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"8","key":"pone.0331958.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18302","article-title":"Surveillance of multidrug-resistant tuberculosis in sub-Saharan Africa through wastewater-based epidemiology","volume":"9","author":"HN Mtetwa","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"pone.0331958.ref012","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijmyco.2016.02.004","article-title":"High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis\/rifampicin in Ghana","volume":"5","author":"JK Boakye-Appiah","year":"2016","journal-title":"Int J Mycobacteriol"},{"issue":"1","key":"pone.0331958.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-022-04331-2","article-title":"Malaria in pregnancy control and pregnancy outcomes: a decade\u2019s overview using Ghana\u2019s DHIMS II data","volume":"21","author":"GD Ampofo","year":"2022","journal-title":"Malar J"},{"key":"pone.0331958.ref014","doi-asserted-by":"crossref","unstructured":"Odei-lartey EO, Kyerewaa R, Prah D, Anane EA, Danwonno H, Gyaase S. Utilization of the national cluster of district health information system for health service decision-making at the district, sub-district and community levels in selected districts of the Brong Ahafo region in Ghana. 2020;5:1\u201315.","DOI":"10.1186\/s12913-020-05349-5"},{"key":"pone.0331958.ref015","doi-asserted-by":"crossref","DOI":"10.1177\/20503121231171350","article-title":"Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda","volume":"11","author":"O Kushemererwa","year":"2023","journal-title":"SAGE Open Med"},{"issue":"9","key":"pone.0331958.ref016","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/tmi.13638","article-title":"TB or not TB? Definitive determination of species within the Mycobacterium tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis","volume":"26","author":"PM Mbelele","year":"2021","journal-title":"Trop Med Int Health"},{"key":"pone.0331958.ref017","first-page":"1","article-title":"Treatment outcomes and associated factors among patients with multidrug- resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross- sectional study","author":"V Panford","year":"2022","journal-title":"BMJ Open"},{"key":"pone.0331958.ref018","doi-asserted-by":"crossref","unstructured":"Basingnaa A, Antwi-baffour S, Nkansah DO, Afutu E, Owusu E. Multidrug Resistant Tuberculosis and Drug Responsive Tuberculosis Patients in Ghana. 2018.","DOI":"10.3390\/diseases7010002"},{"issue":"8","key":"pone.0331958.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287966","article-title":"Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan","volume":"18","author":"A Massud","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"pone.0331958.ref020","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.18203\/2394-6040.ijcmph20192345","article-title":"Socio-demographic determinants of treatment outcome in multidrug resistant tuberculosis cases registered under Programmatic management of drug resistant tuberculosis services in Amritsar, Punjab","volume":"6","author":"M Nagpal","year":"2019","journal-title":"Int J Community Med Public Health"},{"key":"pone.0331958.ref021","volume-title":"Harmonised health facility assessment Ghana HHFA implementation update and preliminary findings","author":"PP Monitoring","year":"2023"},{"issue":"1","key":"pone.0331958.ref022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40249-023-01107-x","article-title":"Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"12","author":"N Salari","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"pone.0331958.ref023","first-page":"8340746","article-title":"Phenotypic and genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates from Sudanese patients","volume":"2017","author":"SMA Sabeel","year":"2017","journal-title":"Tuberc Res Treat"},{"issue":"4","key":"pone.0331958.ref024","doi-asserted-by":"crossref","DOI":"10.1017\/dmp.2020.230","article-title":"Extensively Drug-Resistant Tuberculosis in the Time of COVID-19-How has the Landscape Changed for Pakistan?","volume":"14","author":"M Islam","year":"2020","journal-title":"Disaster Med Public Health Prep"},{"key":"pone.0331958.ref025","first-page":"1","article-title":"Drug-Resistant Tuberculosis and COVID-19: A Scoping Review on a New Threat to Antimicrobial Resistance","volume":"76","author":"BPM da Silva","year":"2023","journal-title":"Rev Bras Enferm"},{"key":"pone.0331958.ref026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2147\/JMDH.S341130","article-title":"COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia","volume":"15","author":"GJ Caren","year":"2022","journal-title":"J Multidiscip Healthc"},{"issue":"2","key":"pone.0331958.ref027","doi-asserted-by":"crossref","DOI":"10.52225\/narra.v3i2.220","article-title":"Risk factors of MDR-TB and impacts of COVID-19 pandemic on escalating of MDR-TB incidence in lower-middle-income countries: a scoping review","volume":"3","author":"I Ichsan","year":"2023","journal-title":"Narra J"},{"issue":"1","key":"pone.0331958.ref028","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12879-023-08463-x","article-title":"Influence of COVID-19 on the notification of drug-resistant pulmonary tuberculosis cases","volume":"23","author":"NH Orf\u00e3o","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"6","key":"pone.0331958.ref029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270272","article-title":"Prevalence of multidrug-resistant tuberculosis in East Africa: A systematic review and meta-analysis","volume":"17","author":"KA Molla","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"pone.0331958.ref030","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3201\/eid2603.191145","article-title":"Mycobacterium tuberculosis Complex Lineage 3 as Causative Agent of Pulmonary Tuberculosis, Eastern Sudan1","volume":"26","author":"YA Shuaib","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"pone.0331958.ref031","unstructured":"Dean A, Dodd P, Floyd K, Glaziou P. Methods for estimating the incidence of drug-resistant TB. 2022;2."},{"key":"pone.0331958.ref032","doi-asserted-by":"crossref","unstructured":"Ismail M. Regional disparities in the distribution of Sudan\u2019s health resources. 2020;26(9).","DOI":"10.26719\/emhj.20.056"},{"key":"pone.0331958.ref033","unstructured":"Hajissa K, Marzan M, Idriss MI. Prevalence of drug-resistant tuberculosis in Sudan: 2021;1\u201319."},{"issue":"6","key":"pone.0331958.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252819","article-title":"The burden of drug resistance tuberculosis in Ghana; results of the First National Survey","volume":"16","author":"AA Sylverken","year":"2021","journal-title":"PLoS One"},{"key":"pone.0331958.ref035","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.2147\/IDR.S277477","article-title":"Prevalence and determinants of multidrug-resistant tuberculosis in Makkah, Saudi Arabia","author":"K Sambas","year":"2020","journal-title":"Infect Drug Resist"},{"issue":"1","key":"pone.0331958.ref036","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1186\/s12913-021-07057-0","article-title":"Causes of multidrug-resistant tuberculosis from the perspectives of health providers: challenges and strategies for adherence to treatment during the COVID-19 pandemic in Brazil","volume":"21","author":"LLL Souza","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"pone.0331958.ref037","unstructured":"Soussa. Prevalence of drug-resistant tuberculosis and associated factors * Preval\u00eancia de tuberculose drogarresistente e fatores associados. 2021. 1\u20138."},{"issue":"3","key":"pone.0331958.ref038","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jadohealth.2022.10.036","article-title":"Caring for Adolescents and Young Adults With Tuberculosis or at Risk of Tuberculosis: Consensus Statement From an International Expert Panel","volume":"72","author":"SS Chiang","year":"2023","journal-title":"J Adolesc Health"},{"key":"pone.0331958.ref039","doi-asserted-by":"crossref","first-page":"105897","DOI":"10.1016\/j.rmed.2020.105897","article-title":"Drug resistance of previously treated tuberculosis patients with diabetes mellitus in Shandong, China","volume":"163","author":"W-M Song","year":"2020","journal-title":"Respir Med"},{"issue":"1","key":"pone.0331958.ref040","first-page":"1","article-title":"Association between body mass index and newly diagnosed drug-resistant pulmonary tuberculosis in Shandong, China from 2004 to 2019","volume":"21","author":"mei Song W","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"1","key":"pone.0331958.ref041","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12879-020-05028-0","article-title":"Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study","volume":"20","author":"A Diallo","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0331958.ref042","doi-asserted-by":"crossref","first-page":"17552","DOI":"10.1038\/s41598-020-74432-y","article-title":"Prevalence and factors associated with multidrug-resistant tuberculosis in South India","volume":"10","author":"SS Shivekar","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0331958.ref043","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/nu14010212","article-title":"Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review","volume":"14","author":"C D\u2019Alessandro","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"pone.0331958.ref044","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cmi.2017.02.013","article-title":"Body mass index and the risk of infection - from underweight to obesity","volume":"24","author":"J Dobner","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"pone.0331958.ref045","volume-title":"Household Health Survey","author":"HH Survey","year":"2017"},{"key":"pone.0331958.ref046","doi-asserted-by":"crossref","first-page":"100411","DOI":"10.1016\/j.jctube.2023.100411","article-title":"Resistance to pyrazinamide in Mycobacterium tuberculosis complex isolates from previously treated tuberculosis cases in Southwestern Oromia, Ethiopia","volume":"34","author":"G Balay","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"pone.0331958.ref047","doi-asserted-by":"crossref","first-page":"1047659","DOI":"10.3389\/fpubh.2022.1047659","article-title":"Drug resistance patterns and dynamics of tuberculosis in Zhejiang Province, China: Results from five periodic longitudinal surveys","volume":"10","author":"L Zhou","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"pone.0331958.ref048","first-page":"1","article-title":"Risk factors for multidrug-resistant tuberculosis","volume":"50","author":"CM Rumende","year":"2018","journal-title":"Acta Med Indones"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0343420","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000}}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331958","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:27:55Z","timestamp":1757438875000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331958"}},"subtitle":[],"editor":[{"given":"Igor","family":"Mokrousov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331958","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}